Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) Director Patrick J. Heron acquired 1,335 shares of the stock in a transaction dated Tuesday, March 4th. The stock was bought at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the purchase, the director now owns 163,643 shares of the company's stock, valued at $7,457,211.51. The trade was a 0.82 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Mirum Pharmaceuticals Price Performance
Shares of MIRM stock opened at $43.42 on Friday. The firm has a market cap of $2.13 billion, a P/E ratio of -21.50 and a beta of 1.04. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The business's 50 day moving average price is $47.18 and its 200-day moving average price is $43.47. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. On average, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. Lord Abbett & CO. LLC bought a new position in Mirum Pharmaceuticals in the third quarter worth approximately $28,913,000. Loomis Sayles & Co. L P acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter worth about $19,473,000. State Street Corp grew its position in Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company's stock worth $69,955,000 after purchasing an additional 297,511 shares during the period. Erste Asset Management GmbH acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $10,136,000. Finally, Raymond James Financial Inc. acquired a new stake in Mirum Pharmaceuticals in the 4th quarter worth about $10,611,000.
Analyst Upgrades and Downgrades
MIRM has been the subject of a number of research analyst reports. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. HC Wainwright upped their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Citigroup upped their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $58.20.
View Our Latest Analysis on MIRM
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
